Sensyne Health PLC Appointment of Joint Broker and Financial Adviser (6694Q)

TIDMSENS

RNS Number : 6694Q

Sensyne Health PLC

22 October 2019

Appointment of Liberum as Joint Broker and Financial Adviser

Oxford, UK; 22 October 2019: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, announces that it has appointed Liberum Capital Limited ("Liberum") as joint broker and financial adviser, with immediate effect, alongside Peel Hunt who are joint broker and joint financial adviser and nominated adviser to the Company.

-ENDS-

For more information please contact:

 
                                                 [phone] 
 Sensyne Health (www.sensynehealth.com)           1845 
 Lord (Paul) Drayson, Chief Executive Officer 
 Lorimer Headley, Chief Financial Officer 
 
   Peel Hunt LLP (Nominated Adviser and Joint      + 44 (0) 20 7418 
   Broker)                                         8900 
 Dr Christopher Golden 
 James Steel 
 Oliver Jackson 
 
                                                 + 44 (0) 20 3100 
 Liberum (Joint Broker)                           2000 
 Bidhi Bhoma 
 Euan Brown 
 
 Consilium Strategic Communications              [phone] 
 Mary-Jane Elliott 
 Sukaina Virji 
 Melissa Gardiner 
 [e-mail] 
 

About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care's 'Initial Code of Conduct for data-driven health and care technology.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information, please visit: www.sensynehealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

APPGMMZGKZZGLZG

(END) Dow Jones Newswires

October 22, 2019 02:00 ET (06:00 GMT)